Updated Peptide Sample Tracker
US$ 20.75
semaglutide sketchy Patients struggle as compounded GLP-1 access rapidly shrinks Novo Nordisk is slashing GLP-1
Description
Publicly available data from the ESSENCE trial do not allow an assessment of blood tests and other NITs that predict response to treatment (and this is generally an unmet need in clinical trials of MASH pharmacotherapy)
Haqq AM, Chung WK, Dollfus H, Haws RM, Martos-Moreno G, Poitou C, et al
Results In the SURPASS-2 trial, at baseline, 19% of participants were on target for attaining no standard goals, 59% for one goal and 21% for two or more goals
It isnt absorbed into the bloodstream in any significant amount
